GlassScriptPhysician profile
Natasha D Wegesa
NPI 1801377023
$1,975.83
in general payments reported to CMS, 2019-2025
22 companies · $526 in 2025
The $526 reported for 2025 was more than what a typical Adult Health (Clinical Nurse Specialist) provider received nationally (typical 2025 total: $186).
See the full distribution for Adult Health (Clinical Nurse Specialist)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $588 · 2022: $47.33 · 2023: $11.00 · 2024: $803 · 2025: $526.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,024 · Travel and Lodging: $317.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,023.94 |
| Travel and Lodging | $316.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axonics, INC. | $484.61 | 2024 | Axonics |
| Procept Biorobotics Corporation | $322.43 | 2024-2025 | Aquabeam System |
| Atricure, INC. | $193.57 | 2021 | |
| Boston Scientific Corporation | $134.99 | 2021-2025 | Spaceoar Vue System - 10ml |
| Janssen Pharmaceuticals, INC | $128.58 | 2021 | |
| Ferring Pharmaceuticals INC. | $86.52 | 2025 | Adstiladrin |
| Endo USA, INC. | $74.11 | 2024-2025 | Xiaflex, Aveed |
| Cvrx, INC. | $72.68 | 2021-2023 | Barostim Neo System |
| Dendreon Pharmaceuticals LLC | $60.81 | 2024-2025 | Provenge |
| Sumitomo Pharma America, INC. | $60.36 | 2025 | Orgovyx |
| Olympus America INC. | $54.55 | 2025 | Itind System |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $47.40 | 2021 | |
| Progenics Pharmaceuticals, INC. | $35.62 | 2025 | |
| Teleflex LLC | $35.48 | 2024-2025 | Barrigel, Urolift |
| Pfizer INC. | $34.68 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| 180 Medical, INC. | $28.38 | 2025 | |
| Myriad Genetic Laboratories, INC. | $27.57 | 2025 | Myrisk |
| Davol INC. | $25.19 | 2021 | |
| Sanofi-Aventis U.S. LLC | $23.06 | 2021 | |
| Antares Pharma, INC. | $17.91 | 2024 | Xyosted |
| Janssen Biotech, INC. | $14.73 | 2025 | Erleada |
| Medtronic, INC. | $12.60 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Natasha Wegesa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.